ロード中...
PI-3 kinase p110β: a therapeutic target in advanced prostate cancers
Prostate cancers in the castration-resistant stage are life-threatening because they are not curable in clinic. The novel androgen receptor inhibitor Xandi (Enzalutamide) and the new CYP17 inhibitor Zytiga (Abiraterone) prolonged patient survival only a few months in advanced prostate cancers. There...
保存先:
| 出版年: | Am J Clin Exp Urol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
e-Century Publishing Corporation
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4219313/ https://ncbi.nlm.nih.gov/pubmed/25374921 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|